Senate Bill 771 Summary

• Prohibits pharmaceutical companies from engaging in direct-to-consumer advertising of prescription drugs in Oklahoma, including via television, radio, print, digital platforms, social media, billboards, email, and text messaging.

• Establishes violations as felony offenses punishable by fines up to $500,000 and/or imprisonment up to 5 years, with each instance of prohibited advertising constituting a separate offense.

• Exempts educational materials from health care providers to patients, internal health care communications, federally/state-required communications, public health campaigns, clinical trial recruitment, insurance coverage information, and patient assistance programs.

• Cites findings that direct-to-consumer advertising exploits public understanding, drives higher drug prices, compromises doctor-patient relationships, and has caused harm through campaigns for OxyContin, Vioxx, and Zyprexa.

• Takes effect July 1, 2025, with an emergency clause allowing immediate effect upon passage and approval.